{"id":"W2989830802","doi":"10.1016/j.euo.2019.11.001","title":"Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; CancerCare Manitoba; Health Sciences Centre; University of Manitoba; Princess Margaret Cancer Centre; University of Calgary","funders":"Instituto de Salud Carlos III; Genentech; Eisai; American Psychosocial Oncology Society; Exelixis; North Carolina GlaxoSmithKline Foundation; EMD Serono; Novartis; Merck; F. Hoffmann-La Roche; Roche; Astellas Pharma US; Health Research Fund of Central Denmark Region; Dana-Farber Cancer Institute; Pfizer; Ipsen Biopharmaceuticals; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001245648,0.0001903877,0.0005306208,0.0004418565,0.0004101007,0.0005943791,0.0003665197,0.0003796424,0.0009560571],"category_scores_gemma":[0.003396317,0.0001441331,0.0009634413,0.0008644314,0.0001946375,0.0004611891,0.0003967544,0.000709085,0.0001129208],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009175434,"about_ca_system_score_gemma":0.0007424626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002914865,"about_ca_topic_score_gemma":0.003355572,"domain_scores_codex":[0.9992595,0.0001739782,0.00008865603,0.000157558,0.0001607756,0.000159435],"domain_scores_gemma":[0.9963042,0.0004477469,0.002506789,0.0001081397,0.0002372224,0.0003960082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006429862,0.00008844286,0.9968748,0.00002173054,0.0001016607,0.00007930787,0.00003013634,0.0001866968,0.00008813763,0.00001513012,0.0001416888,0.001729165],"study_design_scores_gemma":[0.00008449134,0.000800977,0.9974598,0.000021446,0.0001362987,0.0003829874,0.00007964577,0.0004685028,0.0001079765,0.00005054166,0.0003993801,0.000007861273],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980683,0.0006253558,0.00006996443,0.00009291075,0.00001004262,0.00001728903,0.0007910185,0.000002572467,0.0003227083],"genre_scores_gemma":[0.998536,0.0001375237,0.00004015426,0.00003348544,0.00001846788,0.00001706667,0.001144498,0.000001067262,0.00007183053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002914865,"threshold_uncertainty_score":0.006657243,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0106048798008899,"score_gpt":0.2301214897779839,"score_spread":0.219516609977094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}